Skip to main content
Download PDF

Correction: γ‑Secretase modulator resistance of an aggressive Alzheimer‑causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds

Alzheimer's Research & Therapy volume 17, Article number: 83 (2025) Cite this article

The Original Article was published on 19 February 2025

Correction: Alz Res Therapy 17, 49 (2025)

https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13195-025-01680-3


Following the publication of the original article [1], the e-files in the Supplementary Information section were out of sync resulting in the missing Supplementary material 14 e-file. The missing Supplementary material 14 file is given here.

The original article [1] has been updated.

Reference

  1. Trambauer J, Sarmiento RMR, Garringer HJ, et al. γ-Secretase modulator resistance of an aggressive Alzheimer-causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds. Alz Res Therapy. 2025;17:49. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13195-025-01680-3.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), LMU Munich, Feodor‑Lynen‑Str. 17, Munich, 81377, Germany

    Johannes Trambauer & Harald Steiner

  2. German Center for Neurodegenerative Diseases (DZNE), Munich, 81377, Germany

    Johannes Trambauer, Liliana D. Pedro & Harald Steiner

  3. Pharma Research and Early Development, F. Hoffmann-La Roche AG, Therapeutic Modalities, Small Molecule Research, Roche Innovation Center Basel, Basel, 4070, Switzerland

    Rosa Maria Rodriguez Sarmiento

  4. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

    Holly J. Garringer, Ruben Vidal & Bernardino Ghetti

  5. Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, 81377, Germany

    Katja Salbaum, Liliana D. Pedro, Dennis Crusius & Dominik Paquet

  6. Munich Cluster of Systems Neurology (SyNergy), Munich, 81377, Germany

    Dominik Paquet

  7. Pharma Research and Early Development, F. Hoffmann-La Roche AG, Neuroscience and Rare Diseases Translational Area, Neuroscience Discovery, Roche Innovation Center Basel, Basel, 4070, Switzerland

    Karlheinz Baumann & Lothar Lindemann

Authors
  1. Johannes Trambauer
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Rosa Maria Rodriguez Sarmiento
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Holly J. Garringer
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Katja Salbaum
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Liliana D. Pedro
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Dennis Crusius
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Ruben Vidal
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Bernardino Ghetti
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Dominik Paquet
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Karlheinz Baumann
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Lothar Lindemann
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. Harald Steiner
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Harald Steiner.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trambauer, J., Sarmiento, R.M.R., Garringer, H.J. et al. Correction: γ‑Secretase modulator resistance of an aggressive Alzheimer‑causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds. Alz Res Therapy 17, 83 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13195-025-01723-9

Download citation

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13195-025-01723-9

Alzheimer's Research & Therapy

ISSN: 1758-9193